|
業務類別
|
Biotechnology |
|
業務概覽
|
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. |
| 公司地址
| 500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129 |
| 電話號碼
| +1 617 337-4680 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.solidbio.com |
| 員工數量
| 121 |
| Dr. Paul Herzich, PhD |
Chief Technology Officer |
-- |
23/04/2026 |
| Dr. Jessie Hanrahan, PhD |
Chief Regulatory and Preclinical Operations Officer |
-- |
23/04/2026 |
| Mr. David Tyronne Howton |
Chief Operating Officer and Secretary |
美元 513.42K |
23/04/2026 |
| Mr. Kevin Tan |
Treasurer, Chief Financial Officer and Principal Accounting Officer |
-- |
23/04/2026 |
| Dr. Gabriel Brooks, M.D. |
Chief Medical Officer |
美元 502.16K |
23/04/2026 |
| Mr. Alexander G. Cumbo |
President, Chief Executive Officer and Director |
美元 650.99K |
23/04/2026 |
|
|
| Dr. Clare Kahn, PhD |
Independent Director |
23/04/2026 |
| Dr. Georgia Keresty, M.P.H.,PhD |
Independent Director |
23/04/2026 |
| Ms. Lynne Sullivan |
Independent Director |
23/04/2026 |
| Mr. Adam Stone |
Independent Director |
23/04/2026 |
| Mr. Ilan Ganot |
Director |
23/04/2026 |
| Dr. Martin Freed, F.A.C.P.,M.D. |
Independent Director |
23/04/2026 |
| Dr. Sukumar Nagendran, M.D. |
Independent Director |
23/04/2026 |
| Mr. Ian F. Smith |
Executive Chairman of the Board |
23/04/2026 |
| Mr. Alexander G. Cumbo |
President, Chief Executive Officer and Director |
23/04/2026 |
|
|
|
|
